CD226 and neoplasm: Similarly, there was no difference in the expression of activating receptors CD16, NKG2D, NKp30, NKp46, and DNAM-1 after tumor exposure with or without TIGIT blockade, although there was a trend toward a decreased expression of NKG2D upon spheroid exposure, particularly with isotype control (Supplementary Figure S7).